IVME Competitors

IVME Stock  USD 0.0001  0.00  0.00%   
In Veritas Medical competes with Rackspace Technology, Sphere Entertainment, Datadog, NetSol Technologies, and Iridium Communications; as well as few others. The company conducts business under Capital Markets sector and is part of Financials industry. Analyzing In Veritas competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of In Veritas to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out In Veritas Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of In Veritas competition on your existing holdings.
  
The current year's Return On Tangible Assets is expected to grow to -244.5. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, In Veritas' Debt To Assets are projected to increase based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 88.52, whereas Net Tangible Assets are forecasted to decline to (6.7 M).
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.00010.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.0000840.00
Details

In Veritas Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between In Veritas and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of IVME and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of In Veritas Medical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RDCMDDOG
RDCMRBC
RBCDDOG
NTWKSPHR
NTWKRXT
IRDMDDOG
  
High negative correlations   
RBCNTWK
RBCSPHR
DDOGSPHR
RDCMSPHR
RDCMNTWK
NTWKDDOG

Risk-Adjusted Indicators

There is a big difference between IVME Stock performing well and In Veritas Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze In Veritas' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare In Veritas Medical and related stocks such as Rackspace Technology, Sphere Entertainment, and Datadog Net Income Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesRoic
Inventory TurnoverNet Income Per Share
Days Of Inventory On HandPayables Turnover
Sales General And Administrative To RevenueResearch And Ddevelopement To Revenue
Capex To RevenuePocfratio
Interest CoverageCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Income QualityRoe
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Current RatioReceivables Turnover
Debt To EquityRevenue Per Share
Debt To AssetsDividend Yield
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesFree Cash Flow Per Share
Average InventoryCash Per Share
Payout RatioNet Current Asset Value
Tangible Asset ValueNet Debt To E B I T D A
Tangible Book Value Per ShareGraham Number
Shareholders Equity Per ShareCapex Per Share
Graham Net NetAverage Receivables
Interest Debt Per ShareEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityDividend Payout Ratio
Enterprise Value MultipleOperating Cycle
Cash Conversion Cycle
201020112012201320142015201620172018201920202021202220232024
RXT(59.9 M)(59.9 M)(59.9 M)(59.9 M)(59.9 M)(59.9 M)(59.9 M)(59.9 M)(470.6 M)(102.3 M)(245.8 M)(218.3 M)(804.8 M)(837.8 M)(795.9 M)
SPHR(77.3 M)(77.3 M)(77.3 M)(77.3 M)(77.3 M)(77.3 M)(108.5 M)6.9 M(8.2 M)181.7 M(148.2 M)(194.4 M)502.8 M(200.6 M)(190.6 M)
DDOG(2.6 M)(2.6 M)(2.6 M)(2.6 M)(2.6 M)(2.6 M)(2.6 M)(2.6 M)(10.8 M)(16.7 M)(24.5 M)(20.7 M)(50.2 M)48.6 M51 M
NTWK(585.5 K)2.4 M7.9 M(11.4 M)(5.5 M)3.4 M(5 M)4.3 M12 M937.1 K1.8 M1.1 M(5.2 M)683.9 K718.1 K
IRDM(3.8 K)39.7 M64.6 M62.5 M75 M7.1 M111 M233.9 M(13.4 M)(162 M)(56.1 M)(9.3 M)8.7 M15.4 M16.8 M
RBC3.6 M50 M56.3 M60.2 M58.2 M63.9 M70.6 M87.1 M105.2 M120.3 M90.1 M42.7 M166.7 M209.9 M220.4 M
RDCM100 K(1.9 M)(6 M)(1.4 M)726 K(923 K)1.9 M2.9 M(2.4 M)(6.8 M)(4 M)(5.3 M)(2.3 M)3.7 M3.9 M

In Veritas Medical and related stocks such as Rackspace Technology, Sphere Entertainment, and Datadog Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in In Veritas Medical financial statement analysis. It represents the amount of money remaining after all of In Veritas Medical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

In Veritas Competitive Analysis

The better you understand In Veritas competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, In Veritas' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across In Veritas' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IVME RXT SPHR DDOG NTWK IRDM RBC RDCM
 0.00 
 0.0001 
IVME
 0.41 
 2.42 
Rackspace
 1.84 
 38.71 
Sphere
 0.83 
 155.61 
Datadog
 0.73 
 2.71 
NetSol
 0.66 
 30.00 
Iridium
 1.80 
 320.49 
RBC
 1.84 
 12.19 
Radcom
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Current Valuation
Operating Margin
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Return On Asset
Book Value Per Share
Number Of Shares Shorted
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

In Veritas Competition Performance Charts

Five steps to successful analysis of In Veritas Competition

In Veritas' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by In Veritas Medical in relation to its competition. In Veritas' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of In Veritas in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact In Veritas' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to In Veritas Medical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your In Veritas position

In addition to having In Veritas in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Electronics Thematic Idea Now

Electronics
Electronics Theme
Companies manufacturing electronic appliances and goods. The Electronics theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
View All  Next Launch
When determining whether In Veritas Medical is a strong investment it is important to analyze In Veritas' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact In Veritas' future performance. For an informed investment choice regarding IVME Stock, refer to the following important reports:
Check out In Veritas Correlation with its peers.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In Veritas. If investors know IVME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In Veritas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(6.48)
The market value of In Veritas Medical is measured differently than its book value, which is the value of IVME that is recorded on the company's balance sheet. Investors also form their own opinion of In Veritas' value that differs from its market value or its book value, called intrinsic value, which is In Veritas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In Veritas' market value can be influenced by many factors that don't directly affect In Veritas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In Veritas' value and its price as these two are different measures arrived at by different means. Investors typically determine if In Veritas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In Veritas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.